ClinicaliQ Trial Snapshot
- A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 — Recruiting • Phase II • NCT06667453.
- This trial tests whether a new medicine (PGN-EDODM1) is safe and works for people with myotonic dystrophy type 1.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo. Conditions: Myotonic Dystrophy 1 Interventions: PGN-EDODM1, Placebo Lead Sponsor: PepGen Inc Planned Enrollment: 24 participants